HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a Buy rating on ADMA Biologics (NASDAQ:ADMA) and increased the price target from $5 to $6.
January 09, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADMA Biologics' stock may see a positive short term impact due to the Buy rating reaffirmation and raised price target from $5 to $6 by HC Wainwright & Co.
Analyst ratings and price target adjustments are significant indicators for investors, often leading to increased investor confidence and potential stock price movement. The increase from $5 to $6 represents a bullish outlook on the company's future performance, which could lead to short term price appreciation.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100